Public Company Edition: Alumis grosses $250m after it planned to raise up to $317.7m in its IPO. Also, Zealand adds $1bn in a post-data offering, Tectonic and Eliem close $130.7m and $120m private placements to support recent mergers, and Ginkgo cuts 35% of its workforce.

Ensho Therapeutics is raising series A cash to develop Phase II-ready NSHO-101 (EA1080), a third oral ɑ4β7 integrin inhibitor attempting to take on Takeda’s blockbuster injectable Entyvio.

VX-880 is the first iteration of a cell therapy strategy which Vertex believes can bring curative treatment for Type 1 diabetes, but competition in this field is building.

The radiopharmaceutical developer abandoned its NASDAQ IPO at the eleventh hour. What now?